China Detains Five AstraZeneca Employees Over Data Privacy and Drug Import Violations

Investigations focus on unapproved liver cancer drug and potential breaches of data privacy laws.

Five current and former AstraZeneca employees, all Chinese citizens, are under investigation.
Authorities are probing the importation of an unapproved liver cancer drug.
The investigation also examines possible violations of China's data privacy laws.
AstraZeneca employs around 16,000 people in China, contributing significantly to its revenue.
The detentions come amid broader anti-corruption and regulatory crackdowns in China's healthcare sector.